What does the ESMO guidelines consider prognostic indicators for hairy cell leukemia (HCL)?

Updated: Sep 16, 2018
  • Author: Emmanuel C Besa, MD; Chief Editor: Koyamangalath Krishnan, MD, FRCP, FACP  more...
  • Print

Although no international prognostic system for risk stratification of HCL has been developed, ESMO guidelines consider the following clinical variables to indicate an adverse prognosis [16] :

  • Severe cytopenias (hemoglobin [Hgb] < 10 g/dL, platelets < 100 × 10 9/L, neutrophils < 1 ×10 9/L )
  • Lymphadenopathy
  • Presence of TP53 mutations and lack of somatic mutations in the IGVH genes

In addition, the ESMO guidelines note that patients who achieve a complete response (CR) have a significantly longer disease-free survival than those who achieve a partial response. [16]

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!